191 related articles for article (PubMed ID: 26915463)
61. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
[TBL] [Abstract][Full Text] [Related]
62. Targeting BTK in CLL: Beyond Ibrutinib.
Bond DA; Woyach JA
Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669
[TBL] [Abstract][Full Text] [Related]
63. Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
Naydenov AV; Taylor LP
Oncologist; 2019 Sep; 24(9):1237-1245. PubMed ID: 30842245
[TBL] [Abstract][Full Text] [Related]
64. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
[No Abstract] [Full Text] [Related]
65. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
66. Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
Fischer A; Bastian S; Cogliatti S; Mey U; Saub J; Schanz U; Padberg B; Hohloch K
Hematol Oncol; 2018 Feb; 36(1):370-371. PubMed ID: 28681549
[No Abstract] [Full Text] [Related]
67. NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation.
Mikudina B; Goodall M; Adler AI
Lancet Oncol; 2017 Mar; 18(3):289-290. PubMed ID: 28130034
[No Abstract] [Full Text] [Related]
68. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
69. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
Int J Cancer; 2020 Jan; 146(1):85-93. PubMed ID: 31180577
[TBL] [Abstract][Full Text] [Related]
70. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
Molica S
Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545
[TBL] [Abstract][Full Text] [Related]
71. Ibrutinib in the real world patient: many lights and some shades.
Ghia P; Cuneo A
Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711
[No Abstract] [Full Text] [Related]
72. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
Mato AR; Timlin C; Ujjani C; Skarbnik A; Howlett C; Banerjee R; Nabhan C; Schuster SJ
Br J Haematol; 2018 Apr; 181(2):259-261. PubMed ID: 28220935
[No Abstract] [Full Text] [Related]
73. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
74. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
January
Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
[TBL] [Abstract][Full Text] [Related]
75. Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.
Skrabs C; Pickl WF; Perkmann T; Jäger U; Gessl A
J Clin Pharm Ther; 2018 Feb; 43(1):145-149. PubMed ID: 28753229
[TBL] [Abstract][Full Text] [Related]
76. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
77. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
78. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
[No Abstract] [Full Text] [Related]
79. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
Gohil SH; Evans R; Harasser M; El-Kholy M; Paredes-Moscosso SR; Della Peruta M; Nathwani AC
Br J Haematol; 2019 Jul; 186(2):380-382. PubMed ID: 30957227
[No Abstract] [Full Text] [Related]
80. Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
Sachanas S; Pangalis GA; Moschogiannis M; Yiakoumis X; Koulieris E; Tsirkinidis P; Kalpadakis C; Rontogianni D
Anticancer Res; 2017 Jun; 37(6):3277-3280. PubMed ID: 28551676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]